Highlights From the 2017 Annual European MS Meeting

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Systemic Lupus Erythematosus

New Psoriasis Treatments

Treatment Algorithms in Melanoma: Past, Present, and Future

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Updates on Emerging GLP-1 Receptor Agonists

Dual Antiretroviral Therapy

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Improving Acne Outcomes

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Assessing Disease Progression in MS Treatment

Optimizing Management of Advanced Bladder Cancer

Management Challenges in CLL

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Novel Approaches in T1D Management

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Treating to Target in MS

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Guide to Atopic Dermatitis

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

Pregnancy in MS.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

Emerging Multiple Sclerosis Therapies

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Updates in Progressive MS

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Highlights From the 2017 Annual European MS Meeting

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. The program will also include a discussion of off-label treatment not approved by the FDA for use in the U.S.

Investigational Disease-Modifying Therapies for MS

Long-Term Lymphocyte Counts in Patients With RRMS Treated With Cladribine Tablets, 3.5 mg/kg

Cladribine: Background

Long-Term Lymphocyte Counts and Cladribine

Long-Term Lymphocyte Counts and Cladribine: Results

Radiologic Outcomes of Cladribine in Patients With MS and HAD: Background

Radiologic Outcomes of Cladribine in Patients with MS and HAD: Post Hoc Analysis

Radiologic Outcomes of Cladribine in Patients with MS and HAD: Results

Concluding Remarks

Biomarkers for Prognostication in Early MS

Purpose of Biomarkers in MS

Neurofilaments

NfL Concentrations and CIS Objectives and Methods

NfL Concentrations and CIS Results

NfL Concentrations and CIS Conclusions

Intrathecal Ig in MS Background

Intrathecal Ig in MS Aim and Study Design

Intrathecal Ig in MS Results

Overall Conclusions

What Is New in Progressive Forms of MS?

Risk of SPMS Methods

Risk of SPMS Results

Predicting MS Disease Progression From Placebo Arms

Predicting MS Disease Progression From Placebo Arms Statistical Methods, Definitions, and Baseline Factors

Predicting MS Disease Progression From Placebo Arms Results

PPMS Misdiagnosis in Europe and US Background

PPMS Misdiagnosis in Europe and US Methods

PPMS Misdiagnosis in 5EU and U.S. Results

PPMS Misdiagnosis in 5EU and US Conclusions

Brain Reserve and Cognitive Reserve in Progressive MS Methods

Brain Reserve and Cognitive Reserve in Progressive MS Results

Exposure to DMTs Among Pregnant Women With MS

Background

Pregnancy Incidence and Therapy Exposure in MS Methods

Pregnancy Incidence and Therapy Exposure in MS Results

Pregnancy Outcomes With Alemtuzumab Background

Pregnancy Outcomes With Alemtuzumab Results

Pregnancy Outcomes With Cladribine Background

Pregnancy Outcomes With Cladribine Results

Conclusions

Abbreviations

Abbreviations (cont)